Search Results - "Hanse, Monique C. J."

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial by Taal, Walter, MD, Oosterkamp, Hendrika M, MD, Walenkamp, Annemiek M E, MD, Dubbink, Hendrikus J, PhD, Beerepoot, Laurens V, MD, Hanse, Monique C J, MD, Buter, Jan, MD, Honkoop, Aafke H, MD, Boerman, Dolf, MD, de Vos, Filip Y F, MD, Dinjens, Winand N M, PhD, Enting, Roelien H, MD, Taphoorn, Martin J B, MD, van den Berkmortel, Franchette W P J, MD, Jansen, Rob L H, MD, Brandsma, Dieta, MD, Bromberg, Jacoline E C, MD, van Heuvel, Irene, Vernhout, René M, MSc, van der Holt, Bronno, PhD, van den Bent, Martin J, Prof

“…Summary Background Treatment options for recurrent glioblastoma are scarce, with second-line chemotherapy showing only modest activity against the tumour…”
Get full text

Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial by Erdem-Eraslan, Lale, van den Bent, Martin J, Hoogstrate, Youri, Naz-Khan, Hina, Stubbs, Andrew, van der Spek, Peter, Böttcher, René, Gao, Ya, de Wit, Maurice, Taal, Walter, Oosterkamp, Hendrika M, Walenkamp, Annemiek, Beerepoot, Laurens V, Hanse, Monique C J, Buter, Jan, Honkoop, Aafke H, van der Holt, Bronno, Vernhout, René M, Sillevis Smitt, Peter A E, Kros, Johan M, French, Pim J

“…The results from the randomized phase II BELOB trial provided evidence for a potential benefit of bevacizumab (beva), a humanized monoclonal antibody against…”
Get full text

Predicting disease progression in high-grade glioma with neuropsychological parameters: the value of personalized longitudinal assessment by Butterbrod, Elke, Bruijn, Jimme, Braaksma, Meriam M., Rutten, Geert-Jan M., Tijssen, Cees C., Hanse, Monique C. J., Sitskoorn, Margriet M., Gehring, Karin

“…Purpose Progressive disease in patients with high-grade glioma may be reflected in cognitive decline. However, the cognitive functions most sensitive to…”
Get full text

The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial by Dirven, Linda, van den Bent, Martin J, Bottomley, Andrew, van der Meer, Nelly, van der Holt, Bronno, Vos, Maaike J, Walenkamp, Annemiek M.E, Beerepoot, Laurens V, Hanse, Monique C.J, Reijneveld, Jaap C, Otten, Aja, de Vos, Filip Y.F.L, Smits, Marion, Bromberg, Jacoline E.C, Taal, Walter, Taphoorn, Martin J.B

“…Abstract Background The BELOB study, a randomised controlled phase 2 trial comparing lomustine, bevacizumab and combined lomustine and bevacizumab in patients…”
Get full text

Acute neurological disorders following intraperitoneal administration of cisplatin by Simkens, Geert A.A.M, Hanse, Monique C.J, de Hingh, Ignace H.J.T

Get full text